

TAKING PUBLICLY FUNDED R&D IN INDIA TO THE MARKETS : LESSONS FROM NCL



Dr. S. Sivaram
National Chemical Laboratory,
Pune-411 008, INDIA

ACTIV WORKSHOP
VENTURE CENTER, PUNE

Tel : 0091 20 2590 2600

Fax : 0091 20 2590 2601

Email : s.sivaram@ncl.res.in

September 27, 2010

Visit us at : <http://www.ncl-india.org>



**THE PURPOSE OF THIS LABORATORY IS TO ADVANCE
KNOWLEDGE AND TO APPLY CHEMICAL SCIENCE FOR
THE GOOD OF THE PEOPLE**

J W McBain



NCL : A SNAP SHOT


- Established : 1950
- Location : Pune, India
- Total personnel
 - Permanent Staff : 730
 - Scientific : 206
 - Technical : 330
 - Administrative : 194
 - Research Fellows (CSIR, UGC) : 440
 - Project Staff (M.Sc's) : 382
 - Post doctoral fellows : 24

One of the largest publicly funded research institution in India
One of the oldest research institutions of independent India

SCIENCE → SOLUTIONS → MARKETS

- Desirable
- Feasible
- Viable


PARTNERSHIP IS ESSENTIAL FOR SCIENCE TO REACH THE STAKEHOLDERS



CREATING VALUE TO ITS CUSTOMERS

- NCL's portfolio of programs include process and product development, reaction engineering, pilot plant experiments, process design and engineering, process simulation and modeling, computational modeling, technical consulting and continuing education
- NCL has the capability to deliver solutions to customers across the full spectrum, from laboratory scale development to design and operation of batch and continuous pilot plants and preparation of basic engineering packages for chemicals, polymer and materials
- NCL is focused on creating value to customers through innovations, IP, development of non-infringing processes and science based understanding of complex phenomena

NATURE OF RESEARCH






TRANSLATIONAL MODELS PRACTISED AT NCL

- **Contract Research wherein value addition occurs outside of India**
- **Contract research wherein value additions occur within India**
- **Technology development through Public – Private Partnerships**
- **IP licensing followed by technology development**
- **Technology licensing followed by incubation of start up enterprises**



CONTRACT RESEARCH WHEREIN VALUE ADDITION OCCURS OUTSIDE OF INDIA




P&G



**Hierarchical structures with
graded layer porosities**



Always, the world's leader in feminine protection, is dedicated to helping women embrace womanhood positively—from the very beginning of puberty through their adult lives.

The Always brand is behind some of the biggest innovations in feminine hygiene history, including the introduction of winged pads in 1985 and Ultra thin pads in 1990. Continuing its goal of improving women's lives across the world, **Always recently introduced Always Infinity, a pad made with a new-to-the-world material that enables women to have the magical combination of absorbency, amazing softness, and flexibility all in one pad.**



P&G

Polymer microcapsules for fabric care



MASTER COLLABORATION AGREEMENT

BETWEEN

THE PROCTER & GAMBLE COMPANY

AND

COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

P&G

Preamble

This Master Agreement for RESEARCH & COLLABORATION (or "MCA"), effective on the last date of execution of this MCA ("MCA EFFECTIVE DATE"), is by and between COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH, having a principal place of business at Anusandhan Bhawan, 2 Rafi Marg, New Delhi, 110 001 (hereinafter collectively referred to along with its AFFILIATES as "CSIR"), and The Procter & Gamble Company, (hereinafter collectively referred to along with its AFFILIATES as "P&G"), a corporation of Ohio, having a principal place of business at One Procter & Gamble Plaza, Cincinnati, Ohio 45202.

1 Background of the Agreement

P&G has unique skills, technology and know-how specific to the development and use of consumer product formulations desired by consumers, and has the ability to manufacture and sell such products globally.

FOR: COUNCIL OF SCIENTIFIC &
INDUSTRIAL RESEARCH

FOR: THE PROCTER & GAMBLE
COMPANY

By: [Signature]

By: [Signature]

Name: Dr. R. A. Mashelkar

Name: Larry Huston

Title: Director General, CSIR

Title: VP Innovation

Date: 3/30/2005

Date: 3/23/2005



CONTRACT RESEARCH WHEREIN VALUE ADDITIONS OCCUR WITHIN INDIA

OPERATING PROCESS TECHNOLOGIES



Research performed
on demand for
global companies;
however, manufacturing
established in India



THPE
Excel Ind. Ltd
(2002)



Vinyl Carboxylates
Mehik Ltd
(2010)



TECHNOLOGY DEVELOPMENT THROUGH PUBLIC – PRIVATE PARTNERSHIPS

PRODUCTS IN MARKET



PanPure S-Pantoprazole 20mg tablets

CHIRALLY PURE
CLINICALLY SURE

Scores over Pantoprazole

- Efficacy
- Safety
- Affordability

Only Rs. **3.9/-** per day

Peptic ulcer

GERD (including Nocturnal)

Co-Rx with NSAIDs

2005

S (-) Amlodipine Besilate Tablets
Asomex-2.5

5 blister strips of 10 tablets each.

Emcure

S (-) Amlodipine Besilate Tablets
Asomex-2.5

5 blister strips of 10 tablets each.

Mfg. Lic. No. : PD-133
Batch No. : NAL.021
Mfg. Date : AUG. 2002
Exp. Date : JULY 2004
Retail Price not to exceed Rs. : 19.50 per strip of 10 tablets
Local taxes extra.
Mfd. at : C-7-812, M.I.D.C., BHOSARI, PUNE-411026

Composition :
Each uncoated tablet contains :
S (-) Amlodipine Besilate equivalent to S (-) Amlodipine 2.5 mg.
Colour : Yellow Oxide of Iron
Manufactured by :
Emcure
PHARMACEUTICALS LTD.
DAPODI, PUNE - 411 012, INDIA.
Trade Mark Owners.

Dosage : As directed by the Physician.
Store in a cool, dry & dark place.

Warning : To be sold by retail on the prescription of a Registered Medical Practitioner only.

2003

EMCURE PHARMACEUTICALS , PUNE

PROCESS TECHNOLOGIES TRANSFERRED



GBL, 2007



ABG, 2008



GBL, 2010




IP LICENSING FOLLOWED BY TECHNOLOGY DEVELOPMENT

SOLID CATALYSTS FOR BIODIESEL


- A range of fresh, used, edible and non-edible oils can be used
- Non aqueous process; no aqueous effluent; anhydrous glycerol obtained as byproduct
- Transesterification with methanol as well as octanol
- No leaching of catalyst into the reaction mixture
- Catalyst is reusable and easily separable.
- Can tolerate high levels of free fatty acids
- Continuous, fixed bed process
- Biodiesel quality meets desired specifications for fuel applications

Veg. Oil Biodiesel Glycerol



Several issued and applied patents to NCL/CSIR have been licensed to Benefuel, USA

Management Expertise



Strategic Partners



- One of largest catalyst producers in world
- 5,000 person, publically traded company
- Global production capacity



- Market leader for crude oil dewatering using electrostatic separation
- Co-developed novel method for separating biodiesel & glycerin



- One of the world's largest catalytic research institutes
- Government backed institute with over 200+ PhD's
- Focus on catalysis since 1980



- Ravi Randhava, PhD. – CTO**
- Founder of Xytel – 700+ world wide process engineering company
 - Focus on solid catalyst technology development





TECHNOLOGY LICENSING FOLLOWED BY INCUBATION OF START UP ENTERPRISES



UF MEMBRANE TECHNOLOGY : FROM CONCEPT TO MARKET

- **Discovery of a unique process to control membrane porosity**
 - Reject smallest known pathogenic species (virus);
 - Still be able to operate at tap water pressure (0.4 bar)
- **Prototype preparation, demonstration & performance evaluation**
 - Designed various easy to use prototypes
 - Demonstration & rigorous performance evaluation
- **Technology transfer**
 - Technology licensed to Membrane Filters India Ltd., Pune, a start up enterprise incubated at NCL
 - Product in the market since 2007; Current sales turnover of the company ~ US\$ 15 million

POROUS POLYETHYLENE IMPLANTS – IN THE MARKET!



BIOPORE™
ISO 13485:2003 & CE certified

HOME | About us | Email

BIOPORE™ PRODUCT FEATURES
BIOPORE™ biomaterial Implants are manufactured from linear high density polyethylene.

BIOPORE™ PRODUCTS

- BIOPORE™ Extended Inferior Orbital Rim Implants
- BIOPORE™ Extended Malar Contoured Implants
- BIOPORE™ Nasal Dorsum Shapes
- BIOPORE™ Nasal Augmentation Sheet
- BIOPORE™ Chin Implant-two-piece-well Contoured
- BIOPORE™ Mandible Implant
- BIOPORE™ Sheets
- BIOPORE™ TissueBlock® Implants
- BIOPORE™ Orbital Spheres
- BIOPORE™ Orbital Spheres FSSC®

Weaved by Shivaami Corporation

Copyright © 2009. All Rights Reserved.



Sphere with suture tunnels



Orbital floor plate




Floor plate (part non-porous)



Orbital rim



Malar implant




Nasal augmentation sheet



Mandibular implant



Nasal dorsum



Chin implant



Pterional implant




Mastoid




Start-up company
www.biopore.in



Technology Commercialization v1.0



LINKING KNOWLEDGE TO MARKETS



TODAYS SCIENCE SEEDING TOMORROW'S TECHNOLOGIES




- **Advanced and functional materials including nanomaterials**
- **Nano-structured materials and catalysis for energy conversion and storage (electrochemical, solar)**
- **Novel hybrid materials for harvesting solar energy**
- **Environmentally friendly polymers**
- **Biomaterials, tissue engineering and bio-conjugates for therapeutics**
- **Catalysis, chemical engineering and computational science to leverage clean technologies**
- **Establishing sustainable and /or renewable feedstocks for chemical manufacturing**
- **Harnessing modern biology to create a more sustainable chemical industry**
- **Selective separation processes for a diverse range of applications**



SIGNIFICANT OPPORTUNITIES FOR DISRUPTIVE INNOVATION EXISTS. HOWEVER, TODAY'S CHEMICAL SCIENCE WILL REQUIRE A COMPLETELY DIFFERENT TRANSLATIONAL MODEL TO CONVERT KNOWLEDGE TO WEALTH

Technology Commercialization v2.0



PUBLIC-PRIVATE PARTNERSHIP : CONSORTIUM MODEL


- Areas of common interest to a few companies – access to generic knowledge
- Consortium agreements with service modules
- Project Advisory Boards with company participation
- Benefit sharing and possibility of bilateral projects
- Ownership of IP and proprietary knowledge vests with NCL/CSIR
- Rights of first refusal to consortium partners

Organizational models




Fully owned subsidiary of company or Division of company

- Arms length relationship with NCL
- Shorter-term arrangement



JV between company-NCL
Section 25 company

- NCL presence of Board of Directors, Management Team and Scientific Advisory Board
- Longer term arrangement





NCL INNOVATION PARK

www.innovationpark.org



NCL Innovation Park ... the transformed campus



The planned home for technology innovations and PPPs





www.venturecenter.co.in

Seeding Tomorrow's Enterprises Today

To become the hub for nucleating innovation focused entities of Indian companies, and thus give birth to innovation-focused companies in the chemical and allied disciplines for India

WHY SHOULD SCIENTISTS IN PUBLICLY FUNDED INSTITUTIONS BE INTERESTED IN TRANSLATING SCIENCE INTO PRODUCTS AND SERVICES

- Institutional compulsions and demands
- Challenge of bringing good science to the market
- Creating wealth for the society and to themselves
- Altruism or doing good for the society which nurtured them; desire to act as agents of change in society
- Self actualization and growth motivation (highest in the hierarchy of human needs according to Abraham Maslow)

At the end of the day, every scientist has this yearning for having been useful

BARRIERS TO KNOWLEDGE DRIVEN INNOVATIONS



- Cultural barriers (knowledge is free, making personal wealth out of knowledge is not right, separating the goddess of knowledge from the goddess of wealth in the Indian pantheon of gods)
- Immaturity of markets and risk averse
- Inability to connect basic discoveries with potential applications
- Weak innovation eco systems (mentoring, venture and angel funds, knowledge clusters)
- Poor competence and lack of work experience in science – business interface
- Peer recognition systems heavily biased in terms of abstract academic research; not enough incentives for individuals who wish to translate science into products and services

SOME USEFUL LESSONS LEARNT



- **Invest in good basic / curiosity driven research leading to IPR / high quality publications**
 - Intuition driven
 - New opportunities for generic patent
- **Choose products / processes for development where the entry barrier is likely to be low**
 - Difficult to license technologies
 - Single technology supplier items
 - Products having large transportation cost
 - Formulated or structured products

SOME USEFUL LESSONS LEARNT



- Learn to walk the last mile; science brings quick personal recognitions, whereas , technology take long time before the rewards become apparent
- Putting the team together and energising the team
- Patience , perseverance and failure tolerant
- Who gets the glory and who gets the blame
- The role of a champion; the leader as a champion
- Going beyond the written contract; in the end it is the people who deliver not a piece of paper !
- Passion to succeed; Are you ready to stake your reputation?

Science is an individual effort; technology is a collective endeavour

LEADERSHIP ROLE IN INNOVATION PROCESS

- Leadership that is failure tolerant; views failure as complement to success, not opposite
- Leadership that is fully engaged in the innovation process; close monitoring of activity is a powerful motivator for enhancing innovation
- Leadership that is focused on increasing the organization's intellectual capital
- Leadership that is collaborative, not controlling
- Leadership that is less evaluative, more interpretative
- Leadership that encourages communication; creates avenues for ideas to “bubble up”



In times of change learners inherit the earth, while the learned find themselves beautifully equipped to deal with a world that no longer exists

Eric Hoffer



THANK YOU

